Supernus Pharmaceuticals (SUPN) Announces Publication Of Phase III Study (PROSPER) Results On Oxtellar XR®
2/3/2014 8:49:35 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company, today announced the publication of the Prospective, Randomized Study of Oxcarbazepine extended release in Subjects with Partial Epilepsy Refractory (PROSPER) data on Oxtellar XR. Results of this Phase III pivotal trial will appear in the upcoming March issue of Acta Neurologica Scandinavica, Volume 129, Issue 3, pages 143–153 and is available online at http://onlinelibrary.wiley.com/doi/10.1111/ane.12207/abstract.
Help employers find you! Check out all the jobs and post your resume.
comments powered by